Detalhe da pesquisa
1.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
2.
Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma.
Br J Clin Pharmacol
; 89(1): 316-329, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35981078
3.
Chronic Exposure to Chlorpyrifos Damages Thyroid Activity and Imbalances Hepatic Thyroid Hormones Signaling and Glucose Metabolism: Dependency of T3-FOXO1 Axis by Hyperglycemia.
Int J Mol Sci
; 24(11)2023 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37298533
4.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
5.
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Cancer Sci
; 111(6): 2116-2122, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32297407
6.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(6): 781-794, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097405
7.
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Blood
; 128(4): 497-503, 2016 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27226434
8.
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Front Oncol
; 13: 1271807, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38111533
9.
Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients.
EJHaem
; 3(3): 815-827, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36051011
10.
Pax8 and Nkx2-1 haploinsufficiencies differentially affect liver metabolic pathways.
J Endocrinol
; 253(3): 115-132, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35289766
11.
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Lancet Haematol
; 9(11): e822-e832, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36209764
12.
Ovarian Aging: Role of Pituitary-Ovarian Axis Hormones and ncRNAs in Regulating Ovarian Mitochondrial Activity.
Front Endocrinol (Lausanne)
; 12: 791071, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34975760
13.
Sample-Pooling Strategy for SARS-CoV-2 Detection among Students and Staff of the University of Sannio.
Diagnostics (Basel)
; 11(7)2021 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34206932
14.
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Leukemia
; 35(6): 1722-1731, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32895455
15.
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Leuk Lymphoma
; 60(2): 462-470, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30068263